ASMANEX TWISTHALER

Compare ASMANEX TWISTHALER  to:
Compare
Compare

Generic Name for ASMANEX TWISTHALER

Mometasone furoate 110micrograms/inh, 220micrograms/inh; pwd for oral inhalation, metered-dose inhaler.

Legal Classification:

Rx

Pharmacological Class for ASMANEX TWISTHALER

Steroid.

Manufacturer of ASMANEX TWISTHALER

Schering Corporation

Indications for ASMANEX TWISTHALER

Maintenance treatment of asthma as prophylactic therapy.

Adult dose for ASMANEX TWISTHALER

Previously on bronchodilators alone or inhaled corticosteroids: initially 220mcg once in the PM; max 440mcg daily (either as 220mcg twice daily or 440mcg once daily). Previously on oral corticosteroids (wean gradually): initially 440mcg twice daily; max 880mcg daily. Rinse mouth after use.

Children's dosing for ASMANEX TWISTHALER

<4yrs: not recommended. 4–11yrs: 110mcg once in the PM; max 110mcg daily. Rinse mouth after use.

Contraindications for ASMANEX TWISTHALER

Not for treatment of acute attacks. Milk protein allergy.

Precautions for ASMANEX TWISTHALER

Maintain regular regimen. Infections. If exposed to chickenpox or measles, consider anti-infective prophylactic therapy. Monitor intraocular pressure; bone mineral density if other osteoporosis risk factors exist; and for growth suppression in children; hypercorticism and HPA axis suppression (if occurs, discontinue gradually). If adrenal insufficiency exists following systemic corticosteroids, replacement with inhaled steroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude). Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Pregnancy (Cat. C). Nursing mothers.

Interactions for ASMANEX TWISTHALER

Caution with potent CYP3A4 inhibitors (eg, ketoconazole).

Adverse Reactions for ASMANEX TWISTHALER

Headache, respiratory or other infection, oral candidiasis, dysmenorrhea, musculoskeletal pain, GI upset, allergic rhinitis, sinus congestion, sinusitis, depression, fatigue, pain, bronchospasm (discontinue if occurs). Children: fever, bruise.

How is ASMANEX TWISTHALER supplied?

Twisthaler 110mcg (30 inh)—1
220mcg (30 inh, 60 inh, 120 inh)—1

Related Disease:

Asthma~antiasthmatics

Related Resources

Orphan drug designation granted for aerosolized alpha1-proteinease inhibitor for alpha1-antitrypsin deficiency

February 08, 2010

Talecris Biotherapeutics was granted orphan drug designation by the FDA for the development of an aerosol formulation of alpha1-proteinease inhibitor to treat congenital alpha1-antitrypsin (AAT) deficiency.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Spiriva HandiHaler safety update

January 15, 2010

The FDA announced that data from a recent review of Spiriva HandiHaler (tiotropium dry powder for inhalation, from Boehringer Ingelheim) do not support an increased risk of stroke, heart attack, or death.

Spiriva HandiHaler approved for the reduction of COPD exacerbations

December 21, 2009

Spiriva HandiHaler (tiotropium powder for oral inhalation, from Boehringer Ingelheim and Pfizer) has been approved by the FDA for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

Concentrated Prolastin-C approved for alpha1-antitrypsin (AAT) deficiency

October 19, 2009

The FDA has approved Prolastin-C (alpha1-proteinase inhibitor [human], from Talecris Biotherapeutics), a more concentrated formulation of Prolastin, for the treatment of alpha1-antitrypsin (AAT) deficiency.